“P047 | ONABOTULINUMTOXIN-A EFFECTIVENESS EVALUATION IN CHRONIC MIGRAINE PATIENTS WITH SHORT OR LONG DISEASE HISTORY AND PSYCHIATRIC COMORBIDITIES: AN ITALIAN MULTICENTRIC STUDY (THE BACH STUDY): F. Vernieri1|2, P. Pasqualetti3, M. Marcosano1|2, N. Brunelli4, L. Fofi1, D. Antonio Montisano5, L. Grazzi5, R. Ornello6, C. Rosignoli6, A. Doretti7, E. Colombo7, M. Albanese8, G. Viticchi9, S. Migliore6, S. Sacco6, C. Altamura1|2 | 1Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 2Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; 3Section of Health Statistics and Biometry, Department WHES (Wellbeing, Health & Environmental Sustainability), Sapienza University of Rome, Italy; 4Department of Neurology, Vall d’Hebron Research Institute, Barcelona, Spain; 5Headache Center, IRCCS Fondazione Istituto Neurologico ‘Carlo Besta’, Milano, Italy; 6Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 7Department of Systems Medicine, University of Rome Tor Vergata, Italy; 8IRCCS Istituto Auxologico Italiano, Milano, Italy; 9Neurological Clinic, Experimental and Clinical Medicine Department, Marche Polytechnic University, Ancona, Italy” (2026) Confinia Cephalalgica, 36(s1). doi:10.4081/cc.2026.16003.